期刊
FRONTIERS IN ENDOCRINOLOGY
卷 14, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2023.1195677
关键词
ANP; atrial natriuretic peptide; obesity; leptin; heart failure; insulin resistance; lipolysis
This study investigated the effect of ANP on the levels of the anorexigenic adipokine leptin in healthy humans. The results showed that ANP infusion led to a significant decrease in plasma leptin levels and an increase in free fatty acids, indicating enhanced lipolysis. Additionally, ANP was found to suppress leptin release in human SGBS adipocytes.
IntroductionAtrial natriuretic peptide (ANP), a hormone secreted from the heart, controls cardiovascular and renal functions including arterial blood pressure and natriuresis. ANP also exerts metabolic effects in adipose tissue, liver and skeletal muscle, and interacts with the secretion of adipokines. We tested the hypothesis that ANP lowers concentrations of the anorexigenic adipokine leptin in healthy humans in vivo. MethodsHuman ANP or matching placebo was infused intravenously (iv) into healthy men in a controlled clinical trial. ResultsWithin 135 minutes of iv ANP infusion, we observed an acute decrease in plasma leptin levels compared to controls. Free fatty acids markedly increased with ANP infusion in vivo, indicating activated lipolysis. In human SGBS adipocytes, ANP suppressed leptin release. DiscussionThe study shows that the cardiac hormone ANP reduces the levels of the anorexigenic adipokine leptin in healthy humans, providing further support for ANP as a cardiomyokine in a heart - adipose tissue axis. (registered in the German Clinical Trials Register and the WHO International Clinical Trials Registry Platform was granted under DRKS00024559)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据